ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0335

Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile

Mariko Ogawa-Momohara1, Thomas Vazquez2, Meena Sharma2, Josh Dan3, Grant Sprow3 and Victoria Werth3, 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, B-Cell Targets, Cutaneous, dermatomyositis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation to distinguish the two entities. Although some studies suggest that B cell targeting therapies are effective for the cutaneous manifestations of CLE and DM, responses to anti-CD20 treatment differ between CLE and DM and are independent from the systemic response. We therefore sought to characterize the B/plasma cell compartment in CLE and DM skin to better understand the cutaneous immunopathogenesis of these autoimmune connective tissues diseases.

Methods: We recruited patients from our prospective CLE and DM databases at the University of Pennsylvania with Institutional Review Board approval. Age-matched healthy controls (HC) were selected from the Penn Skin Biology and Disease Resource Center. We performed imaging mass cytometry on 43 archived, lesional skin biopsies (11 DM, 5 ACLE, 7 DLE, 10 SCLE and 10 HC) using 28 distinct cell markers, cytokines, and immunoglobulins to identify the immunophenotype in each group (figure 1).

Results: We found 11 significant lymphocyte cell groups among all samples that included 3 B cell groups (CD138+ CD27+ IgGhigh plasma cell, CD38high+ B cell, and other CD20+ cells), 4 T cell groups (CD4+ T cell, CD8+ T cell, Treg, and CD45RAhighT cell), monocytes, classical dendritic cells (cDC), NK cells, and macrophages (figure 1). Cell counts of T cells/region of interest (ROI) (CD4+, CD8+, Treg and CD45RAhigh) were most upregulated in DLE compared with HC (p< 0.01). CD20+ cells were increased in DM compared to HC (p< 0.001). CD38high B cell counts/ROI were significantly increased in DM and DLE compared to HC (p< 0.01). cDCs were increased in DM compared to HC (p< 0.001) (figure 2, 3). The percentage of NK cells among all lymphocytes cells was highest in HC (figure 1). IL10 was highly expressed in plasma cells relative to other cell types. The number of plasma cells in DM and ACLE was positively correlated with total skin IL10 intensity (r=0.83, r=0.97) and IgG intensity (r=0.9, r=0.92) but not in DLE and SCLE. IFNg+ CD4 T cell, IFNγ+ CD8 T cells, IL6+ CD38high B cells were increased in DLE relative to HC (p< .05, p< .05, p< .01) (figure 2, 3). Between CLE subgroups, CD45RA T, Treg, and IFNγ+ CD45RA T cell/ROI were significantly higher in DLE than SCLE (p< 0.05, p< 0.05, p< 0.01). IFNγ+ CD45RA T cell and IFNγ+ CD20 B cell are higher in DLE than ACLE (p< 0.05).

Conclusion: We identified several differences in the B and T lymphocyte compartments in CLE and DM. DLE skin demonstrated increased T cells and CD38high B cell, whereas CD20+ B cell and cDCs were increased in DM. The primary IL10 producing cell in DM CLE and HC was the plasma cell in the skin.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Ogawa-Momohara, None; T. Vazquez, None; M. Sharma, None; J. Dan, None; G. Sprow, None; V. Werth, GlaxoSmithKline, CLASI.

To cite this abstract in AMA style:

Ogawa-Momohara M, Vazquez T, Sharma M, Dan J, Sprow G, Werth V. Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/multiplexed-mass-cytometry-of-cutaneous-lupus-erythematosus-and-dermatomyositis-skin-an-in-depth-b-cell-directed-immunoprofile/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multiplexed-mass-cytometry-of-cutaneous-lupus-erythematosus-and-dermatomyositis-skin-an-in-depth-b-cell-directed-immunoprofile/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology